CD8A and Cirrhosis: Since specific mediators driving changes in dysfunctional CD8+ T cell subsets in cirrhosis need further investigation, and their clinical relevance is yet to be fully understood, current immunotherapy strategies for cirrhosis predominantly target cells other than CD8+ T cells, such as macrophages.97, 98